OVERACTIVE BLADDER THERAPEUTICS MARKET ANALYSIS

Regional Analysis

Global Overactive Bladder Therapeutics Market: Regional Insights

North America is the largest market share holder of overactive bladder therapeutics attributable to a rise in the prevalence of overactive bladder syndrome, increasing geriatric population and medical advancements. For instance, according to Global Forum on Incontinence (GFI) in 2018, 9% of North American population was dealing with urinary incontinence. Additionally, in 2020 the National Association for Incontinence reported that approximately 25 million adults suffer from urinary incontinence (leakage) in U.S.

The second largest market for overactive bladder therapeutics is considered to be Europe due to increase in research and development investments and rise in the occurrences of overactive bladder syndrome. For instance, in Europe the TRUST ITN project proposed a research training based collaboration between 8 European universities and 3 enterprises with the aim of a better understanding of overactive bladder syndrome related symptoms and to develop novel approaches for its treatment. Other than the mentioned factors, supportive government initiatives also play a prominent role in the growth of overactive bladder syndrome therapeutics market in Europe. For instance, the U.K.’s National Institute for Health and Care Excellence (NICE) provides the benefit of reimbursement every year for patients adopting Botox Therapy for treatment of overactive bladder syndrome.

The Asia-Pacific market is anticipated to grow over the forecast period owing to a rise in the awareness about the overactive bladder syndrome and aggressive marketing strategies of the manufacturers. Additionally, an increase in the U.S Food and Drug Administration approvals for drugs used in the treatment of overactive bladder syndrome drives the growth of market in the Asia Pacific region. For instance, in April 2020 Granules Pharmaceuticals, Inc, owned by Granules India Ltd. got U.S. FDA approval for use of Trospium Chloride capsules for treatment of urine urgency and urine incontinence in patients suffering from overactive bladder syndrome.